Status of oral anticoagulant treatment in patients with nonvalvular atrial fibrillation in Spain. REACT-AF Study;Situación del tratamiento anticoagulante oral en pacientes con fibrilación auricular no valvular en España. Estudio REACT-AF

Revista Clinica Espanola

Volumn 215, Issue 2, 2015, Pages 73-82

  De Andres Nogales F ^a   Oyaguez I ^a   Betegon Nicolas L ^b   Canal Fontcuberta, C ^b   Soto Alvarez J ^c  

^a Pharmacoeconomics and Outcomes Research Iberia (PORIB)   (Spain)

^b BRISTOL MYERS SQUIBB   (United States)

^c PFIZER INC   (United States)

Author keywords

Anticoagulants; Atrial fibrillation; Stroke; Spain; Treatmentcompliance

Indexed keywords

ANTICOAGULANT AGENT;

ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; COHORT ANALYSIS; DRUG CONTROL; DRUG WITHDRAWAL; EUROPEAN; HEART ATRIUM FIBRILLATION; HUMAN; MEDICAL SOCIETY; MEDICATION COMPLIANCE; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; RETROSPECTIVE STUDY; SPAIN; TREATMENT WITHDRAWAL;

EID: 84922935908     PISSN: 00142565     EISSN: 15781860     Source Type: Journal    
DOI: 10.1016/j.rce.2014.08.008     Document Type: Article

References (28)

1. V. Fuster, L.E. Rydén, R.W. Asinger, D.S. Cannom, H.J. Crijns, and R.L. Frye ACC/AHA/ESC Guidelines for the management of patients with atrial fibrillation: executive summary a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology Circulation 104 2001 2118 2150
2. A.J. Camm, G.Y. Lip, R. de Caterina, I. Savelieva, D. Atar, and S.H. Hohnloser 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association Eur Heart J 33 2012 2719 2747
3. V. Barrios, A. Calderón, C. Escobar, and M. de la Figuera Pacientes con fibrilación auricular asistidos en consultas de atención primaria. Estudio Val-FAAP Rev Esp Cardiol 65 2012 47 53
4. J. Guindo, M.D. Martínez, I. Duran, P. Torrnos, and A. Martínez-Rubio Evaluación de riesgo tromboembólico y hemorrágico de los pacientes con fibrilación auricular Rev Esp Cardiol 13 Supl C 2013 9 13
5. A.J. Camm, P. Kirchhof, G.Y. Lip, U. Schotten, I. Savelieva, and S. Ernst European Association for Cardio-Thoracic Surgery Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC) Eur Heart J 31 2010 2369 2429 Erratum in: Eur Heart J. 2011; 32: 1172
6. G.Y. Lip, R. Nieuwlaat, R. Pisters, D.A. Lane, and H.J. Crijns Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation Chest 137 2010 263 272
7. J.L. Navarro, J.M. Cesar, M.A. Fernández, J. Fontcuberta, J.C. Reverter, and J. Gol-Freixa Morbilidad y mortalidad en pacientes con tratamiento anticoagulante oral Rev Esp Cardiol 60 2007 1226 1232
8. J. Polo García Nuevos anticoagulantes frente a anticoagulantes clásicos: ventajas e inconvenientes Semergen 39 Supl 1 2013 10 16
9. J. Mateo Nuevos anticoagulantes orales y su papel en la práctica clínica Rev Esp Cardiol 13 Supl C 2013 33 41
10. C.B. Granger, J.H. Alexander, J.J. McMurray, R.D. Lopes, E.M. Hylek, and M. Hanna Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 2011 981 992
11. J.A. Cramer, A. Roy, A. Burrell, C.J. Fairchild, M.J. Fuldeore, and D.A. Ollendorf Medication compliance and persistence: terminology and definitions Value Health 11 2008 44 47
12. C.M. Dezii Persistence with drug therapy: a practical approach using administrative claims data Manag Care 10 2001 42 45
13. A.M. Peterson, D.P. Nau, J.A. Cramer, J. Benner, F. Gwadry-Sridhar, and M. Nichol A checklist for medication compliance and persistence studies using retrospective databases Value Health 10 2007 3 12
14. J.F. Steiner, and A.V. Prochazka The assessment of refill compliance using pharmacy records: methods, validity, and applications J Clin Epidemiol 50 1997 105 116
15. J.J. Caro, K.J. Ishak, K.F. Huybrechts, G. Raggio, and C. Naujoks The impact of compliance with osteoporosis therapy on fracture rates in actual practice Osteoporos Int 15 2004 1003 1008
16. F.R. Rosendaal, S.C. Cannegieter, F.J. van der Meer, and E. Briët A method to determine the optimal intensity of oral anticoagulant therapy Thromb Haemost 69 1993 236 239
17. J.L. Clua Espuny, M.R. Dalmau Llorca, and C. Aguilar Martín Características del tratamiento anticoagulante oral en la fibrilación auricular crónica de alto riesgo Aten Primaria 34 2004 414 419
18. A. Ringborg, R. Nieuwlaat, P. Lindgren, B. Jönsson, D. Fidan, and A.P. Maggioni Costs of atrial fibrillation in five European countries: results from the Euro Heart Survey on atrial fibrillation Europace 10 2008 403 411
19. M. Ruiz-Ortiz, E. Romo-Peñas, M. Franco-Zapata, D. Mesa-Rubio, M. Anguita-Sánchez, and M. Delgado-Ortega Anticoagulación oral en la fibrilación auricular no valvular: ¿son efectivas y seguras las recomendaciones científicas en la práctica clínica diaria? Rev Esp Cardiol 59 2006 688 695
20. P. Kirchhof, B. Ammentorp, H. Darius, R. de Caterina, J.Y. Le Heuzey, and R.J. Schilling Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events - European Registry in Atrial Fibrillation (PREFER in AF) Europace 16 2014 6 14
21. S. Connolly, J. Pogue, R. Hart, M. Pfeffer, S. Hohnloser, and S. Chrolavicius Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial Lancet 367 2006 1903 1912
22. R.G. Hart, L.A. Pearce, and M.I. Aguilar Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation Ann Intern Med 146 2007 857 867
23. J.L. Clua-Espuny, I. Lechuga-Duran, R. Bosch-Princep, A. Roso-Llorach, A. Panisello-Tafalla, and J. Lucas-Noll Prevalencia de la fibrilación auricular desconocida y la no tratada con anticoagulantes. Estudio AFABE Rev Esp Cardiol 66 2013 545 552
24. E. Giménez-García, J.L. Clua-Espuny, R. Bosch-Princep, C. López-Pablo, I. Lechuga-Durán, and M. Gallofré-López El circuito asistencial de la fibrilación auricular en pacientes ambulatorios: estudio observacional Audit fibrilación auricular en el Baix Ebre Aten Primaria 46 2014 58 67
25. J.M. Lobos-Bejarano, J.C. del Castillo-Rodríguez, A. Mena-González, J.J. Alemán-Sánchez, A. Cabrera de León, and G. Barón-Esquivias Características de los pacientes y abordaje terapéutico de la fibrilación auricular en atención primaria en España: Estudio FIATE Med Clin (Barc) 141 2013 279 286
26. J. Carrasco, F.E. Cotté, I. Duprat Lomon, A. Letierce, M. Huguet, and N. Marchant Adherence to treatment and persistency in patients treated with VKA in France, Italy, Germany, Spain and the UK ISPOR 16th Annual European Congress Research Abstracts Noviembre 2013. Dublin. Value Health 2013 A516 16
27. J. Carrasco, F.E. Cotté, I. Duprat Lomon, A. Letierce, M. Huguet, and N. Marchant Anticoagulation treatment with VKA in France, Italy, Germany, Spain and the UK. Results from the REACT AF study ISPOR 16th Annual European Congress Research Abstracts Noviembre 2013. Dublin. Value Health 2013 A516 16
28. J. Carrasco, F.E. Cotté, I. Duprat Lomon, A. Letierce, M. Huguet, and N. Marchant The use of oral anticoagulation drugs for stroke prevention in non-valvular atrial fibrillation in France, Italy, Germany, Spain and the UK: Is current practice consistent with the 2012 ESC recommendations? ISPOR 16th Annual European Congress Research Abstracts Noviembre 2013. Dublin. Value Health 2013 A516 16